Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 126-131

  Beau Faller, M ^a,b,c   Prim, N ^a,b   Ruppert, A M ^c,d,e   Nanni Metellus I ^f   Lacave, R ^d   Lacroix, L ^g   Escande, F ^h   Lizard, S ⁱ   Pretet, J L ^j   Rouquette, I ^k   de Cremoux P ^l   Solassol, J ^m   de Fraipont, F ⁿ   Bieche I ^o   Cayre, A ^p   Favre Guillevin, E ^q   Tomasini, P ^f   Wislez, M ^c,d,e   Besse, B ^c,g   Legrain, M ^a   Voegeli, A C ^a   Baudrin, L ^c   Morin, F ^c   Zalcman, G ^c,r   Quoix, E ^a,c   Blons, H ^q   Cadranel, J ^c,d,e   more..

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c French speaking Intergroup of Thoracic Oncology (IFCT)   (France)

^d HÔPITAL TENON   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ Centre Anti Cancer GF Leclerc   (France)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

^l INSTITUT CURIE   (France)

^m MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o Center René Huguenin   (France)

^p UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^q HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^r CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Epidermal growth factor receptor mutations; Exon 18 mutations; Exon 20 mutations; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; OBSERVATIONAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE;

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS; EXON 18 MUTATIONS; EXON 20 MUTATIONS; NON-SMALL-CELL LUNG CANCER; TYROSINE-KINASE INHIBITORS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84895450705     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt418     Document Type: Article

References (39)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
2. Paez JG, Jänne PA, Lee JC et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
3. Pao W, Miller V, Zakowski M et al. EGF Receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
4. Murray S, Dahabreh IJ, Linardou H et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008; 3: 832-839.
5. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
7. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
8. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
9. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
10. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539-548.
11. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010; 277: 301-308.
12. Wu JY, Wu SG, Yang CH et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-4882.
13. Wu JY, Yu CJ, Chang YC et al. Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011; 17: 3812-3821.
14. Yasuda H, Kobayashi S, Costa DB. EGFR Exon 20 insertion mutations in nonsmall-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012; 13: e23-e31.
15. Oxnard GR, Jänne PA. Power in numbers: meta-analysis to identify inhibitorsensitive tumor genotypes. Clin Cancer Res 2013; 19: 1634-1636.
16. Yeh P, Chen H, Andrews J et al. DNA-Mutation Inventory to refine and enhance cancer treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 2013; 19: 1894-1901.
17. Massarelli E, Johnson FM, Erickson HS et al. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 2013; 80: 235-241.
18. Kobayashi S, Canepa HM, Bailey AS et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013; 8: 45-51.
19. He M, Capelletti M, Nafa K et al. EGFR Exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012; 18: 1790-1797.
20. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-486.
21. Beau-Faller M, Degeorges A, Rolland E et al. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecularFrench laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project-part 1). J Thorac Oncol 2011; 6: 1006-1015.
22. Cadranel J, Mauguen A, Faller M et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced Non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol 2012; 7: 1490-1502.
23. Forbes SA, Tang G, Bindal N et al. COSMIC (the catalogue of somatic mutations in cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010; 38: D652-D657.
24. Institut National du Cancer: Bonnes pratiques pour la recherche à visée théranostique de mutations somatiques dans les tumeurs solides. Août 2010; http://www.e-cancer.fr/expertises-publications-de-l-inca/rapports-et-exp ertises/soins (8 January 2010, date last accessed)
25. Vallières E, Shepherd FA, Crowley J et al. The IASLC lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 1049-1059.
26. Travis WD, Brambilla E, Noguchi M et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
27. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
28. Cadranel J, Zalcman G, Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J 2011; 37: 183-193.
29. Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol 2012; 7: 775-776.
30. Oxnard GR, Lo PC, Nishino M et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thor Oncol 2013; 8: 179-184.
31. Arcila ME, Nafa K, Chaft JE et al. EGFR Exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013; 12: 220-229.
32. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18: 4910-4918.
33. Mounawar M, Mukeria A, Le Calvez F et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672.
34. Lee YJ, Shim HS, Kang YA et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 937-944.
35. D'Angelo SP, Pietanza MC, Johnson ML et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011; 29: 2066-2070.
36. Couraud S, Zalcman G, Milleron B et al. Lung cancer in never smokers-a review. Eur J Cancer 2012; 48: 1299-1311.
37. Costa DB, Yasuda H, Sng NY et al. Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertions mutations within the tyrosine kinase domain of EGFR. J Clin Oncol 2012; 30: (15_Suppl): 7523.
38. Kancha RK, Peschle C, Duyster J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol 2011; 6: 387-392.
39. Chen YR, Fu YN, Lin CH et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006; 25: 1205-1215.